Disclosures for "A Two-part, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib (Part A) and the Effect of Fenebrutinib on the QT/QTc Interval in Healthy Participants (Part B)"
-
Ms. Xu has nothing to disclose.
-
Mr. Kuruvilla has received personal compensation for serving as an employee of Genentech. Mr. Kuruvilla has stock in Genentech.
-
Dr. Ratchford has received personal compensation for serving as an employee of Genentech. Dr. Ratchford has stock in F. Hoffman La-Roche.
-
Dr. Qi has nothing to disclose.
-
Dr. Pan has nothing to disclose.
-
Dr. Yu has received personal compensation for serving as an employee of Roche/Genentech.